@article{JTD7010,
author = {Qianwen Liu and Zhitao Gu and Fu Yang and Jianhua Fu and Yi Shen and Yucheng Wei and Lijie Tan and Peng Zhang and Yongtao Han and Chun Chen and Renquan Zhang and Yin Li and Keneng Chen and Hezhong Chen and Yongyu Liu and Youbing Cui and Yun Wang and Liewen Pang and Zhentao Yu and Xinming Zhou and Yangchun Liu and Jin Xiang and Yuan Liu and Wentao Fang and Members of the Chinese Alliance for Research in Thymomas},
title = {The role of postoperative radiotherapy for stage I/II/III thymic tumor—results of the ChART retrospective database},
journal = {Journal of Thoracic Disease},
volume = {8},
number = {4},
year = {2016},
keywords = {},
abstract = {Background: Postoperative radiotherapy (PORT) for thymic tumor is still controversial. The object of the study is to evaluate the role of PORT for stage I to III thymic tumors.
Methods: The Chinese Alliance for Research in Thymomas (ChART) was searched for patients with stage I to III thymic tumors who underwent surgical resection without neoajuvant therapy between 1994 and 2012. Univariate and multivariate survival analyses were performed. Cox proportional hazard model was used to determine the hazard ratio for death.
Result: From the ChART database, 1,546 stage I to III patients were identified. Among these patients, 649 (41.98%) received PORT. PORT was associated with gender, histological type (World Health Organization, WHO), thymectomy extent, resection status, Masaoka-Koga stage and adjuvant chemotherapy. The 5-year and 10-year overall survival (OS) rates and disease-free survival (DFS) rates for patients underwent surgery followed by PORT were 90% and 80%, 81% and 63%, comparing with 96% and 95%, 92% and 90% for patients underwent surgery alone (P=0.001, P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/7010}
}